Breaking News Instant updates and real-time market news.

ALXN

Alexion

$136.80

4.51 (3.41%)

, PRNB

Principia Biopharma

$33.84

0.66 (1.99%)

04:55
03/27/19
03/27
04:55
03/27/19
04:55

SVB Leerink to hold a conference

SVB Leerink Biotech Mountain Meeting will be held in Jackson Hole, WY on March 25-27.

ALXN

Alexion

$136.80

4.51 (3.41%)

PRNB

Principia Biopharma

$33.84

0.66 (1.99%)

RDUS

Radius Health

$19.00

0.58 (3.15%)

IFRX

InflaRx

$40.58

-2.45 (-5.69%)

ENTA

Enanta

$96.32

1.45 (1.53%)

BHVN

Biohaven Pharmaceutical

$52.85

1.37 (2.66%)

AUPH

Aurinia Pharmaceuticals

$6.61

0.02 (0.30%)

FOLD

Amicus

$13.48

0.21 (1.58%)

  • 01

    Apr

  • 04

    Apr

  • 28

    Jun

ALXN Alexion
$136.80

4.51 (3.41%)

02/22/19
GUGG
02/22/19
INITIATION
Target $135
GUGG
Neutral
Alexion initiated with a Neutral at Guggenheim
Guggenheim analyst Yatin Suneja initiated Alexion with a Neutral rating and $135 price target, stating that he believes much of the growth in Soliris's approved indications is abating and the launch of next-gen Ultomiris could further taper some of the remaining growth. He also sees a lack of meaningful catalysts in the next 12 months.
02/12/19
MSCO
02/12/19
NO CHANGE
Target $175
MSCO
Overweight
Morgan Stanley says survey points to rapid switching to Alexion's Ultomiris
Morgan Stanley analyst Matthew Harrison called the long-term durability of the Soliris/Ultomiris franchise the key investor debate on Alexion, stating that current valuation implies that less than 50% of Soliris patients will switch to the next-generation version. However, the firm's survey points to a rapid switch, with physicians saying they expect 57% of their patients to switch in 6 months and 84% in the first year, Harrison tells investors. He believes robust switching, as supported by the survey data, should drive durable long-term revenue growth and he raised his price target on Alexion shares to $175 from $165 on his switch conviction. Harrison keeps an Overweight rating on Alexion.
02/04/19
PIPR
02/04/19
NO CHANGE
Target $180
PIPR
Overweight
Piper sees 'perplexing disconnect' between Alexion fundamentals, stock price
Piper Jaffray analyst Christopher Raymond sees "yet another perplexing disconnect between fundamentals and stock action" following Alexion Pharmaceuticals' Q4 results. With a beat and above consensus fiscal 2019 earnings guidance, the market seems focused on Alexion's below consensus revenue guidance, Raymond tells investors in a post-earnings research note titled "Q418 Beat, FY19 Revenue Guidance a Bit of a Sandbag; Buyers Right Here." The sales outlook "seems to presuppose everything but the kitchen sink with respect to any type of headwind," says the analyst. He thinks Alexion's management team has continued to deliver without reward from the market. Further, there is "very real potential" for the company to be taken out, Raymond adds. He's a buyer of the stock at current levels with an Overweight rating and $180 price target. Alexion in afternoon trading is down 2% to $123.79.
03/20/19
PIPR
03/20/19
NO CHANGE
PIPR
Overweight
Alexion turnaround 'on full display' at investor meeting, says Piper Jaffray
After attending Alexion's investor day meeting, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating and said he remains a buyer of the stock, stating that he sees the company's two newly announced collaborations with Zealand Pharma and Affibody as a continuation of a recent trend of "bolt-on deals with good strategic logic." He came away from the meeting with increased confidence in management's strategy and ability to execute given data pointing to robust Soliris-to-Ultomiris conversion and rapid Soliris gMG uptake, Raymond added.
PRNB Principia Biopharma
$33.84

0.66 (1.99%)

10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/09/18
LEER
10/09/18
INITIATION
Target $34
LEER
Outperform
Principia Biopharma initiated with an Outperform on sales forecast at Leerink
Leerink analyst Geoffrey Porges started Principia Biopharma with an Outperform rating and $34 price target. The analyst cited his sales forecast for lead asset PRN1008 in orphan diseases, pemphigus and immune thrombocytopenia purpura, which combined he believes can reach peak sales of about $550M risk-adjusted at 65% and 35% probability-of-success, respectively.
10/09/18
LEER
10/09/18
INITIATION
Target $34
LEER
Outperform
Principia Biopharma initiated with an Outperform at Leerink
Leerink started Principia Biopharma with an Outperform rating and $34 price target.
10/09/18
WELS
10/09/18
INITIATION
Target $45
WELS
Outperform
Principia Biopharma initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Principia Biopharma with an Outperform rating and $45 price target. The analyst views the company's drug chemistry platform as "highly leveragable" and feels its lead product targeting BTK for autoimmune disease is differentiated.
RDUS Radius Health
$19.00

0.58 (3.15%)

03/29/18
LEER
03/29/18
INITIATION
Target $53
LEER
Outperform
Radius Health initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges started Radius Health with an Outperform rating and $53 price target as he believes transdermal patch could expand treated market and Tymlos share.
11/13/18
JPMS
11/13/18
NO CHANGE
JPMS
Overweight
Radius Health shares attractive at current levels, says JPMorgan
JPMorgan analyst Jessica Fye left a recent call with Radius Health management encouraged by the progress with the Tymlos launch. The analyst acknowledges key pipeline data will not read out until 2020/2021, she views Radius as an undervalued stock. She expects 2019 to be a year of continued Tymlos growth as well as one of pipeline execution and sees current share levels as attractive entry point at current levels for those with a longer-term time horizon. Fye keeps an Overweight rating on Radius Health.
02/14/19
HCWC
02/14/19
INITIATION
Target $22
HCWC
Neutral
Radius Health initiated with a Neutral at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao started Radius Health with a Neutral rating and $22 price target. The company's osteoporosis and nascent oncology portfolios can drive value, but there are "potential head winds before those are realized," says the analyst.
IFRX InflaRx
$40.58

-2.45 (-5.69%)

02/05/19
JPMS
02/05/19
NO CHANGE
Target $65
JPMS
Overweight
InflaRx price target raised to $65 from $42 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for InflaRx to $65 from $42 ahead of the Phase 2b Shine study of IFX-1 In hidradenitis suppurativa. The data readout, expected in Q2, "largely remains an under the radar catalyst," Rama tells investors in a research note. The analyst continues to believe the Shine study has a high probability of success and the potential to be a "transformational catalyst" for InflaRx shares. Rama sees share upside potential from the readout ranging from 60% to 150%-plus versus downside in the 40%-55% range. He reiterates InflaRx as a top pick for the first half of 2019 and keeps an Overweight rating on the name.
02/22/19
GUGG
02/22/19
INITIATION
Target $65
GUGG
Buy
InflaRx initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated InflaRx initiated with a Buy rating and $65 price target, citing his view that early data from lead asset IFX-1 indicate that it could be superior to the current standard of care, Humira, in its lead indication of hidradenitis suppurativa.
12/10/18
FBCO
12/10/18
INITIATION
Target $47
FBCO
Outperform
InflaRx initiated with an Outperform at Credit Suisse
Credit Suisse analyst Tiago Fauth started coverage of InflaRx with an Outperform rating and $47 price target. The analyst believes the stock will outperform based on a favorable risk/reward into a potentially meaningfully de-risking Phase 2b clinical update for IFX-1 in HS and increasing investor recognition of the substantial and growing opportunity in the HS market.
01/28/19
BARD
01/28/19
INITIATION
Target $62
BARD
Outperform
InflaRx initiated with an Outperform at Baird
Baird initiated InflaRX with an Outperform and $62 price target.
ENTA Enanta
$96.32

1.45 (1.53%)

12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
BREN
12/13/18
INITIATION
Target $80
BREN
Hold
Enanta initiated with a Hold at Berenberg
Berenberg analyst Patrick Trucchio initiated Enanta with a Hold rating and $80 price target.
08/08/18
OPCO
08/08/18
DOWNGRADE
OPCO
Perform
Enanta downgraded to Perform from Outperform at Oppenheimer
08/08/18
08/08/18
DOWNGRADE
Target $100

Perform
Enanta downgraded to Perform on HCV headwinds at Oppenheimer
As previously reported, Oppenheimer analyst Jay Olson downgraded Enanta to Perform from Outperform following quarterly results and in the face of HCV headwinds. The analyst lowered his price target on the shares to $100 from $135.
BHVN Biohaven Pharmaceutical
$52.85

1.37 (2.66%)

03/04/19
NEED
03/04/19
NO CHANGE
Target $56
NEED
Buy
Biohaven Pharmaceutical price target raised to $56 from $48 at Needham
Needham analyst Alan Carr raised his price target on Biohaven Pharmaceutical to $56 and kept his Buy rating after its Q4 earnings and his discussions with the management. The analyst points to the company's unchanged expectations for Rimegepant NDA submission for acute migraine being on track for Q2 as well as its phase 3 trial data in migraine prevention remaining on track for Q4 of this year. Based on the drug's "encouraging" long-term phase 3 safety data announced last year, Carr attributes his higher price target to expectations of Rimegepant's greater penetration in the migraine prevention market.
03/18/19
PIPR
03/18/19
NO CHANGE
Target $75
PIPR
Overweight
Biohaven priority review purchase could bring 2019 approval, says Piper Jaffray
Biohaven Pharmaceutical's purchase of a priority review voucher puts rimegepant orally dissolving tablet on track for a potential approval by year-end, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Depending on when the new drug application is filed over the next four months, a rimegepant approval could potentially leapfrog Allergan's (AGN) ubrogepant, says the analyst. He views rimegepant as the "best-in-class oral CGRP" and keeps an Overweight rating on Biohaven with a $75 price target.
03/06/19
CANT
03/06/19
NO CHANGE
Target $82
CANT
Overweight
Biohaven price target raised to $82 from $75 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Biohaven Pharmaceutical to $82 following his recent migraine due diligence, including a doctor survey. The survey suggests that the oral drugs would compete more-than-effectively with current standard of care and new/emerging treatments, including mAb-CGRPs, in not only acute but also preventive indications, Duncan tells investors in a research note. He keeps an Overweight rating on Biohaven shares.
02/01/19
PIPR
02/01/19
NO CHANGE
PIPR
Overweight
Amgen acquisition of Alexion could make a lot of sense, says Piper Jaffray
While most investors anticipate Amgen (AMGN) could be shopping for smaller, bolt-on deals amid increased investor and press speculation that it is now an active acquirer, a larger deal with more near-term accretion potential may make more sense, Piper Jaffray analyst Christopher Raymond tells investors in a research note partially titled "Go Big or Go Home?" He thinks a potential Amgen for Alexion Pharmaceuticals (ALXN) deal "could actually make a lot of sense." Even at levels approaching $200 per share for Alexion, Amgen "could make a strong argument for a business combination," says Raymond. Alexion closed yesterday up $1.64 to $122.96. The analyst admits that some "bolt-on deals have been bandied around" by investors that "arguably make sense" for Amgen, including Biohaven Pharmaceutical and Amarin (AMRN). However, none of these options on their own get Amgen "to where they need to be to address the growth challenges of the legacy franchises," Raymond argues. He thinks a better deal for the company may be Alexion, which would bring in a "long-tailed asset" with Soliris/Ultomiris, an area Amgen has already approached with its Soliris biosimilar effort. The analyst's math has the potential deal being accretive next year, growing to 20%-plus accretion by 2024 for Amgen, even at a takeout price approaching $200 per Alexion share. Raymond keeps Overweight ratings on both companies.
AUPH Aurinia Pharmaceuticals
$6.61

0.02 (0.30%)

08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
03/20/19
RBCM
03/20/19
NO CHANGE
Target $11
RBCM
Outperform
Aurinia Pharmaceuticals price target raised to $11 from $9 at RBC Capital
RBC Capital analyst Douglas Miehm raised his price target on Aurinia Pharmaceuticals to $11 and kept his Outperform rating. The analyst says the company's Q4 results contained "no surprises" as it remains on track for its phase 3 lupus nephritis trial, with the readout expected later this year. Miehm adds that his higher price target reflects his updated model for positive voclosporin IP developments.
03/20/19
CANT
03/20/19
NO CHANGE
Target $24
CANT
Overweight
Aurinia Pharmaceuticals price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $24 from $18 and reiterates an Overweight rating on the shares following the company's Q4 results. The new target reflects Aurinia's recent Notice of Allowance regarding a U.S. patent related to voclosporin's method of use. The analyst no longer anticipate a decrease in the voclosporin price in 2027 from generic entry. However, the largest driver of Aurinia's shares will likely be a focus on Phase 3 data for voclosporin for the treatment of lupus nephritis, which could be announced by year-end 2019, says Piros.
FOLD Amicus
$13.48

0.21 (1.58%)

02/01/19
JPMS
02/01/19
NO CHANGE
Target $19
JPMS
Overweight
Amicus shares undervalued, offer long-term entry point, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Amicus Therapeutics are undervalued and that current levels provide an attractive long-term entry point. He raised his price target for the stock to $19 from $18 and keeps an Overweight rating on the name. The company is trading slightly above Galafold's standalone value, which implies that minimal credit is currently being ascribed to its Pompe program and gene therapy initiatives, Rama tells investors in a research note.
01/30/19
01/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. United Continental (UAL) initiated with a Buy at Argus. 2. Amicus (FOLD) initiated with an Overweight at Cantor Fitzgerald. 3. Take-Two (TTWO) and Zynga (ZNGA) were initiated with a Buy at Goldman Sachs, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Neutral. 4. Sirius XM (SIRI) resumed with a Buy at B. Riley. 5. National Grid (NGG) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/19
CANT
01/29/19
INITIATION
CANT
Overweight
Amicus initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros initiated Amicus with an Overweight rating and $20 price target. The analyst sees Amicus's Galafold as becoming the standard of care for Fabry disease, and views clinical programs and the early stage pipeline as "auspicious," given available data.
01/29/19
CANT
01/29/19
INITIATION
Target $20
CANT
Overweight
Amicus initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Elemer Piros initiated Amicus with an Overweight and $20 price target.

TODAY'S FREE FLY STORIES

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.